The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more ...

Eli Lilly & Co. closed $177.18 short of its 52-week high ($972.53), which the company reached on August 22nd. Supported by ...

Gov. Eric Holcomb said Clay Robbins' "humble service to our great state truly represents the very best of what it means to be ...

After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its ...

American drugmaker Eli Lilly and Company's India unit is set to see a leadership change with managing director ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

Eli Lilly ( LLY 0.91%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...